Skip to Content
Merck
All Photos(1)

Documents

Y0000191

Human glucagon

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Glucagon

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C153H225N43O49S
CAS Number:
Molecular Weight:
3482.75
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

human glucagon

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

InChI

1S/C153H225N43O49S/c1-72(2)52-97(133(226)176-96(47-51-246-11)132(225)184-104(60-115(159)209)143(236)196-123(78(10)203)151(244)245)179-137(230)103(58-83-64-167-89-29-19-18-28-87(83)89)183-131(224)95(43-46-114(158)208)177-148(241)120(74(5)6)194-141(234)101(54-79-24-14-12-15-25-79)182-138(231)105(61-117(211)212)185-130(223)94(42-45-113(157)207)171-124(217)75(7)170-127(220)91(31-22-49-165-152(160)161)172-128(221)92(32-23-50-166-153(162)163)174-146(239)110(69-199)191-140(233)107(63-119(215)216)186-134(227)98(53-73(3)4)178-135(228)99(56-81-33-37-85(204)38-34-81)180-129(222)90(30-20-21-48-154)173-145(238)109(68-198)190-136(229)100(57-82-35-39-86(205)40-36-82)181-139(232)106(62-118(213)214)187-147(240)111(70-200)192-150(243)122(77(9)202)195-142(235)102(55-80-26-16-13-17-27-80)188-149(242)121(76(8)201)193-116(210)66-168-126(219)93(41-44-112(156)206)175-144(237)108(67-197)189-125(218)88(155)59-84-65-164-71-169-84/h12-19,24-29,33-40,64-65,71-78,88,90-111,120-123,167,197-205H,20-23,30-32,41-63,66-70,154-155H2,1-11H3,(H2,156,206)(H2,157,207)(H2,158,208)(H2,159,209)(H,164,169)(H,168,219)(H,170,220)(H,171,217)(H,172,221)(H,173,238)(H,174,239)(H,175,237)(H,176,226)(H,177,241)(H,178,228)(H,179,230)(H,180,222)(H,181,232)(H,182,231)(H,183,224)(H,184,225)(H,185,223)(H,186,227)(H,187,240)(H,188,242)(H,189,218)(H,190,229)(H,191,233)(H,192,243)(H,193,210)(H,194,234)(H,195,235)(H,196,236)(H,211,212)(H,213,214)(H,215,216)(H,244,245)(H4,160,161,165)(H4,162,163,166)/t75-,76+,77+,78+,88-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,120-,121-,122-,123-/m0/s1

InChI key

MASNOZXLGMXCHN-ZLPAWPGGSA-N

Gene Information

human ... GCGR(2642)

Looking for similar products? Visit Product Comparison Guide

Amino Acid Sequence

His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Human glucagon EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Glucagon is a 29-amino acid peptide hormone secreted by pancreatic α-cells that raises blood glucose and (indirectly) insulin levels. Glucagon acts via a G protein-coupled receptor, which results in the release of glucose 1-phosphate from glycogen.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Highly-conserved 29-amino acid polypeptide hormone produced by the pancreatic cells.
Sales restrictions may apply.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?
Deborah Cohen
BMJ (Clinical research ed.), 346, f3680-f3680 (2013-06-12)
Glucagon's yin and yang effects on hepatic glucose production.
Dale S Edgerton et al.
Nature medicine, 19(6), 674-675 (2013-06-08)
Jonathan R Dillman et al.
AJR. American journal of roentgenology, 201(1), 185-189 (2013-06-26)
The objective of our study was to evaluate the use of i.v. glucagon in pediatric patients undergoing MR enterography. Forty-seven patients underwent clinical MR enterography examinations consisting of identical breath-hold T1-weighted 3D gradient-recalled echo fat-saturated pulse sequences before and after
Christian de Duve (1917-2013).
Günter Blobel
Nature, 498(7454), 300-300 (2013-06-21)
Incretin therapy: should adverse consequences have been anticipated?
Edwin Gale
BMJ (Clinical research ed.), 346, f3617-f3617 (2013-06-12)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service